Showing results (1-10 of 109) with videos related to
Sort By:
Pageof 11
Neuropsychiatric Disease and Treatment|January 17, 2012
The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studiesLise Aagaard, Ebba Holme HansenCurrent Drug Safety|August 6, 2013
Adverse Drug Reaction Labeling for Atomoxetine, Methylphenidate and Modafinil: Comparison of Product Information for oral Formulations in Australia, Denmark and the United StatesLise Aagaard, Ebba Holme HansenJournal of Research in Pharmacy Practice|July 4, 2014
Side effects of antineoplastic and immunomodulating medications reported by European consumersLise Aagaard, Ebba Holme HansenJournal of Research in Pharmacy Practice|July 4, 2014
Side effects reported by European consumers for medications for erectile dysfunctionLise Aagaard, Ebba Holme HansenInternational Journal of Clinical Pharmacy|November 6, 2013
Adverse drug reactions in children reported by European consumers from 2007 to 2011Lise Aagaard, Ebba Holme HansenInternational Journal of Clinical Pharmacy|February 25, 2014
Adverse drug reactions associated with asthma medications in children: systematic review of clinical trialsLise Aagaard, Ebba Holme HansenBritish Journal of Clinical Pharmacology|January 19, 2011
Prescribing of medicines in the Danish paediatric population outwith the licensed age group: characteristics of adverse drug reactionsLise Aagaard, Ebba Holme HansenBMC Clinical Pharmacology|March 4, 2009
Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDsLise Aagaard, Ebba Holme HansenInternational Journal of Clinical Pharmacy|October 8, 2014
Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011Lise Aagaard, Ebba Holme HansenCurrent Drug Safety|August 7, 2013
Adverse drug reaction labelling for atomoxetine, methylphenidate and modafinil: comparison of product information for oral formulations in Australia, Denmark and the United StatesLise Aagaard, Ebba Holme HansenPageof 11